 |
Corporate News
25-May-24
|
|
|
|
|
|
|
|
|
|
|
|
Eugia Pharma Specialities' Unit III completes USFDA inspection
|
|
|
|
|
|
|
|
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) had conducted an inspection at Unit III, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Pashamylaram, Patancheru Mandal, Sangareddy District, Telangana, from 22 January to 2 February 2024.
Subsequently, the US FDA has determined the inspection classification status of this facility as ‘Official Action Indicated (OAI)'.
The company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.
|
|
|
|
Previous News |
Nifty hovers above 23,900; PSU bank shares slide
(
Market Commentary
-
Mid-Session
27-Jun-24
14:35
)
|
|
|
Aurobindo Pharma Ltd eases for fifth straight session
(
Hot Pursuit
-
27-Jun-24
13:35
)
|
|
|
Auro Pharma's Telangana facility gets ‘VAI’ classification
(
Hot Pursuit
-
27-Jun-24
13:01
)
|
|
|
Nifty hovers above 23,050; PSU banks in demand
(
Market Commentary
-
Mid-Session
27-May-24
14:30
)
|
|
|
Auro Pharma Q4 PAT jumps 80% YoY to Rs 909 crore
(
Hot Pursuit
-
27-May-24
12:34
)
|
|
|
Aurobindo Pharma consolidated net profit rises 79.50% in the March 2024 quarter
(
Results
-
Announcements
27-May-24
08:39
)
|
|
|
Auro Pharma's Telangana facility gets ‘OAI’ classification
(
Hot Pursuit
-
25-May-24
17:08
)
|
|
|
Eugia Pharma Specialities' Unit III completes USFDA inspection
(
Corporate News
-
25-May-24
12:11
)
|
|
|
Aurobindo Pharma Ltd spurts 0.15%, gains for five straight sessions
(
Hot Pursuit
-
22-May-24
13:00
)
|
|
|
Aurobindo Pharma Ltd spurts 3.21%
(
Hot Pursuit
-
18-May-24
13:05
)
|
|
|
Aurobindo Pharma to table results
(
Corporate News
-
17-May-24
12:42
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|